E
Efrat Luttwak
Researcher at Tel Aviv Sourasky Medical Center
Publications - 22
Citations - 352
Efrat Luttwak is an academic researcher from Tel Aviv Sourasky Medical Center. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 4, co-authored 11 publications receiving 46 citations. Previous affiliations of Efrat Luttwak include Tel Aviv University.
Papers
More filters
Journal ArticleDOI
Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma.
Chava Perry,Chava Perry,Efrat Luttwak,Efrat Luttwak,R. Balaban,Gabi Shefer,Miguel Morales,Anat Amit Aharon,Anat Amit Aharon,Y. Tabib,Yossi Cohen,Yossi Cohen,Noam Benyamini,Noam Benyamini,Ofrat Beyar-Katz,Ofrat Beyar-Katz,M. Neaman,M. Neaman,R. Vitkon,R. Vitkon,N. Keren-Khadmy,Maya Levin,Yair Herishanu,Yair Herishanu,Irit Avivi,Irit Avivi +25 more
TL;DR: In this paper, the humoral immune response to BNT162b2 mRNA COVID-19 vaccine was evaluated in patients with B-NHL who received two vaccine doses 21 days apart and compared with the response in healthy controls.
Journal ArticleDOI
Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing.
Yael C Cohen,Yael C Cohen,Mor Zada,Mor Zada,Shuang-Yin Wang,Chamutal Bornstein,Eyal David,Adi Moshe,Baoguo Li,Shir Shlomi-Loubaton,Moshe E. Gatt,Chamutal Gur,Chamutal Gur,Noa Lavi,Chezi Ganzel,Efrat Luttwak,Efrat Luttwak,Evgeni Chubar,Ory Rouvio,Iuliana Vaxman,Iuliana Vaxman,Oren Pasvolsky,Oren Pasvolsky,Mouna Ballan,Tamar Tadmor,Anatoly Nemets,Osnat Jarchowcky-Dolberg,Olga Shvetz,Meirav Laiba,Ofer Shpilberg,Najib Dally,Irit Avivi,Irit Avivi,Assaf Weiner,Ido Amit +34 more
TL;DR: In this article, a prospective, multicenter, single-arm clinical trial (NCT04065789), combined with longitudinal single-cell RNA-sequencing (scRNA-seq) was conducted to study the molecular dynamics of MM resistance mechanisms.
Journal ArticleDOI
Humoral response rate and predictors of response to BNT162b2 mRNA COVID19 vaccine in patients with multiple myeloma.
Irit Avivi,Irit Avivi,Roi Balaban,Tamir Shragai,Tamir Shragai,Gabi Sheffer,Miguel Morales,Anat Aharon,Noa Lowenton-Spier,Svetlana Trestman,Chava Perry,Chava Perry,Noam Benyamini,Noam Benyamini,Moshe Mittelman,Moshe Mittelman,Yaara Tabib,Yaara Tabib,Tali Bar Lev,Tali Bar Lev,Mor Zavaro,Mor Zavaro,Yair Herishanu,Yair Herishanu,Efrat Luttwak,Efrat Luttwak,Yael C Cohen,Yael C Cohen +27 more
TL;DR: In conclusion, BNT162b2 vaccine was safe and provided a high seropositivity rate in MM patients, independent of treatment type, and older, hypogammaglobulinaemic and heavily pretreated patients had lower response rates.
Journal ArticleDOI
Anti-CD19 CAR-T therapy for EBV-negative posttransplantation lymphoproliferative disease—a single center case series
Efrat Luttwak,Efrat Luttwak,David Hagin,David Hagin,Chava Perry,Chava Perry,Ofir Wolach,Ofir Wolach,Gilad Itchaki,Gilad Itchaki,Odelia Amit,Odelia Amit,Yael Bar-On,Yael Bar-On,Tal Freund,Tal Freund,Sigi Kay,Sigi Kay,Rinat Eshel,Rinat Eshel,Irit Avivi,Irit Avivi,Ron Ram,Ron Ram +23 more
TL;DR: This is the first report demonstrating that patients with EBV-negative refractory PTLD may benefit from CAR-T therapy, similarly to other patients with relapse/refractory DLBCL.
Journal ArticleDOI
[18F]FDG PET-CT in patients with DLBCL treated with CAR-T cell therapy: a practical approach of reporting pre- and post-treatment studies.
Dan Cohen,Efrat Luttwak,Ofrat Beyar-Katz,Ofrat Beyar-Katz,Shir Hazut Krauthammer,Yael Bar-On,Yael Bar-On,Odelia Amit,Odelia Amit,Ronit Gold,Chava Perry,Chava Perry,Irit Avivi,Irit Avivi,Ron Ram,Ron Ram,Einat Even-Sapir,Einat Even-Sapir +17 more
TL;DR: In this paper, the authors identify the specific parameters that should be addressed when reporting PET-CT studies in the clinical setting of CAR-T therapy, and they use SUVmax, TMTV, and TLG in all scans.